bedaquiline and Multiple-Sclerosis

The analysis of benefit and risk is an important aspect of decision-making throughout the drug lifecycle. In this work, the use of a benefit-risk analysis approach to support decision-making was explored. The proposed approach builds on the qualitative US Food and Drug Administration (FDA) approach to include a more explicit analysis based on international standards and guidance that enables aggregation and comparison of benefit and risk on a common basis and a lifecycle focus. The approach is demonstrated on six decisions over the lifecycle (e.g., accelerated approval, withdrawal, and traditional approval) using two case studies: natalizumab for multiple sclerosis (MS) and bedaquiline for multidrug-resistant tuberculosis (MDR-TB).

Topics: Antitubercular Agents; Decision Making; Diarylquinolines; Drug Approval; Humans; Immunologic Factors; Multiple Sclerosis; Natalizumab; Tuberculosis, Multidrug-Resistant; United States; United States Food and Drug Administration